487-66-1

Basic information

• Product Name: 2,5-Dihydro-4-methyl-2,5-dioxo-3-furanpropanoic Acid
• Synonyms: 2,5-Dihydro-4-methyl-2,5-dioxo-3-furanpropanoic Acid;2-(2-Carboxyethyl)-3-methylmaleic Anhydride;3-(4-Methyl-2,5-dioxo-2,5-dihydrofuran-3-yl)propanoic acid;2-propionic-3-methylmaleic anhydride;3-(4-methyl-2,5-dioxo-2,5-dihydrofuran-3-yl)propanoic acid (Related Reference)
• CAS NO: 487-66-1
• Molecular Formula: C₈H₈O₅
• Molecular Weight: 184.14612
• Mol File: 487-66-1.mol
• Article Data: 21

Chemical Properties

• Melting Point: 97.0 to 101.0 °C
• Boiling Point: 391°C at 760 mmHg
• Flash Point: 164.7°C
• Appearance: /
• Density: 1.408g/cm³
• Vapor Pressure: 3.33E-07mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.31±0.10(Predicted)
• CAS DataBase Reference: 2,5-Dihydro-4-methyl-2,5-dioxo-3-furanpropanoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Dihydro-4-methyl-2,5-dioxo-3-furanpropanoic Acid(487-66-1)
• EPA Substance Registry System: 2,5-Dihydro-4-methyl-2,5-dioxo-3-furanpropanoic Acid(487-66-1)

Safety Data

• Hazardous Substances Data: 487-66-1(Hazardous Substances Data)

Usage

General Description

2,5-Dihydro-4-methyl-2,5-dioxo-3-furanpropanoic acid is a chemical compound with the molecular formula C7H8O5. It is a derivative of furan, a heterocyclic organic compound, and is commonly used in the production of pharmaceuticals and agrochemicals. It is also known for its potential antioxidant and anti-inflammatory properties, making it a promising candidate for various medical applications. The compound is typically synthesized through chemical reactions involving furan and other reagents, and it is important to handle it with care due to its potential hazardous properties. Overall, 2,5-Dihydro-4-methyl-2,5-dioxo-3-furanpropanoic acid is a versatile chemical with valuable properties that make it useful in various industries.

InChI:InChI=1/C8H8O5/c1-4-5(2-3-6(9)10)8(12)13-7(4)11/h2-3H2,1H3,(H,9,10)

Upstream product

• 14459-29-1 hematoporphyrin 
• 766-39-2 2,3-Dimethylmaleic anhydride 
• 13192-04-6 dimethyl 2-ketoglutarate 
• 3699-66-9 ethyl 2-diethoxyphosphorylpropionate 
• 496919-84-7 C₁₂H₁₈O₆ 
• 5965-53-7 diethyl 2-ketoglutarate 
• 98453-81-7 2-(bromomethyl)-3-methyl maleic anhydrate 
• 347406-12-6 3-[2,2-Bis(ethoxycarbonyl)]ethyl-4-methyl-2,5-furandione 
• 635-65-4 bilirubin 
• 859950-65-5 4-hydroxy-pentane-1,3,4-tricarboxylic acid 
• 1501-06-0 diethyl 2-acetylglutarate 
• 154222-94-3 3-pentene-1,3,4-tricarboxylic acid 1,3,4-triethyl ester 
• 577-53-7 C₈H₁₀O₆ 
• 493-90-3 mesoporphyrin IX 

Downstream Products

• 487-65-0 3-(4-methyl-2,5-dioxo-2,5-dihydro-pyrrol-3-yl)-propionic acid 
• 110-15-6 succinic acid 

Relevant articles and documents

Synthetic Studies on Tautomycin Synthesis of 2,3-Disubstituted Maleic Anhydride Segment

The 2,3-disubstituted maleic anhydride segment of tautomycin has been synthesized in optically active form.Oxidation of 3,4-disubstituted furan employing singlet oxygen completes the construction of the maleic anhydride moiety.Esterification of the maleic anhydride segment without protecting anhydride moiety resulted in the successful coupling reaction with fragment derived from tautomycin.

A medusa-like β-cyclodextrin with 1-methyl-2-(2'-carboxyethyl) maleic anhydrides, a potential carrier for pH-sensitive drug delivery

We developed a new pH-sensitive drug delivery carrier based on β-cyclodextrin (β-CD) and 1-methyl-2-(2'-carboxyethyl) maleic anhydrides (MCM). The primary hydroxyl groups of β-CD were successfully attached to MCM residues to produce a medusa-like β-CD-MCM. The MCM residue was conjugated with cephradine (CP) with high efficiency (>90%). More importantly, β-CD-MCM-CP responded to the small pH drop from 7.4 to 5.5 and released greater than 80% of the drugs within 0.5h at pH 5.5. In addition, the inclusion complex between β-CD-MCM-CP and the adamantane derivative was formed by simple mixing to show the possibility of introducing multi-functionality. Based on these results, β-CD-MCM can target weakly acidic tissues or organelles, such as tumours, inflammatory tissues, abscesses or endosomes, and be easily modified with various functional moieties, such as ligands for cell binding or penetration, enabling more efficient and specific drug delivery.

Nano clustering enzyme with hypoxia activation prodrug and preparation method and application of enzyme

The invention provides a nano clustering enzyme with a hypoxia activation prodrug. The nano clustering enzyme has capacity of targeted tumor hunger and hypoxia activation and is a mode for cancer treatment through cooperation of a chemotherapy and metabolic treatment. An adopted cross-linking agent material polyethylene glycol-b-poly(2-hydroxyethyl methacrylate)segmented copolymer modified by 2-carboxyethyl cellulose-3-methyl maleic anhydride has the acidity response characteristic and can have specificity in tumor targeting breaking. The nano clustering enzyme takes a bovine serum albumin-hypoxia activation drug as a shell, the bovine serum albumin has good biocompatibility and stability so that the nano clustering enzyme can stably exist in the blood, the blood circulation time is prolonged, and the tumor gathering effect is improved. Through the shell, advanced exposure of the enzyme in a core can be avoided, and the toxicity to the normal tissue is lowered. The nano clustering enzyme has good stability and dispersity and is beneficial to biological application.

Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinet